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Summary. Summary: Little is known about depressive and anxious symptoms and quality of life
(QOL) in caregivers of children with cystic ﬁbrosis (CF). The aims of this study were to: (1) assess
rates of female and male caregiver depressive and anxious symptoms, and (2) evaluate relations
between depressive and anxious symptoms, caregiver QOL, and health outcomes. Patients and
Methods: Eligible participants were caregivers of children with CF who completed three
questionnaires assessing depressive and anxious symptoms and caregiver QOL during routine
CF Clinic appointments. Results: Rates of depressive and anxious symptoms were elevated in
female and male caregivers of children with CF . Rates were higher for anxious (51% for females,
43% for males) than depressive symptoms (20–28% for females; 14–31% for males). Female
caregiver depressive symptoms increased as child lung functioning decreased. As depressive
and anxious symptoms increased, caregiver QOL decreased. In addition, female caregiver
depressive and anxious symptoms were positively correlated with male caregiver anxious and
depressive symptoms in a small subsample of couples. CF disease severity and caregiver
depressive symptoms predicted caregiver QOL. Conclusion: Rates of depressive and anxious
symptoms are high among caregivers of children with CF . The results of this study highlight the
needtoscreenforfemaleandmalecaregiverdepressiveandanxioussymptomsintheCFClinicas
CF Team members are well positioned to provided assistance around solving CF-related
challenges. In addition, alleviation of depressive and anxious symptoms could potentially lead to
improvements in the psychological functioning and well-being of caregivers of children with CF .
Pediatr Pulmonol. 2009; 44:784–792.  2009 Wiley-Liss, Inc.
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INTRODUCTION
Cystic ﬁbrosis (CF) is diagnosed in 1 in  3,400 people
in the United States.
1–3 It is the most common life-
shortening, autosomal recessive disorder among Cauca-
sians and affects  30,000 children and adults in the
United States.
3 Caregivers (e.g., biological parents,
grandparents, foster parents, etc.) of children with CF
may experience a variety of signiﬁcant stressors such as
guilt for having passed a genetic disease to one’s child,
quarterly appointments with CF healthcare teams, time-
consuming and complex treatment regimens, hospital-
izations due to pulmonary exacerbations, marital role
strain, decreased amount of time spent in recreational
activities and with other family members, and shortened
life expectancy of the child.
4,5 Increased disease-related
stressorsandcaregiverburdencanpotentiallyleadtopoor
parental adaptation,
6 such as increased depressive and
anxious symptoms and decreased caregiver quality of life
(QOL).
A limited number of studies have assessed depressive
symptoms in caregivers of children with CF. Rates are
high, with 36–44% of female caregivers experiencing
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7,8 In contrast, information about
male caregivers is generally underrepresented in the
extant pediatric chronic illness literature
9,10 for a variety
of reasons including challenges with recruiting fathers
since mothers generally accompany children to medical
appointments.
9 In fact, several studies have demonstrated
that fathers can be successfully recruited when their
inclusion is a goal ofthe research.
7,8 In the limitedstudies
available, 12–33% of male caregivers reportedly experi-
enced depressive symptoms.
7,8 Notably, Glasscoe et al.
8
recently reported that in 22% of couples, both caregivers
experienced elevated depressive symptoms. Although
these studies provide preliminary evidence for the
prevalence of depressive symptoms in caregivers of
children with CF, they were conducted with caregivers
of young children (e.g.,  11 years). Thus, the current
literature does not represent the full child and adolescent
age range and limits our understanding of caregiver
experiences of depression, particularly as their children’s
lung functioning decreases with increased age.
11 Despite
the high comorbidity between anxiety and depression, no
studies have assessed anxious symptoms in caregivers of
children with CF. In addition, little is known about
the impact of CF on caregiver QOL. Boling
12 and
colleagues
13developedaQOLquestionnaireforcaregivers
of children with CF, which assesses physical, emotional,
family, and social functioning. Results from these studies
indicated that QOL among caregivers of children with
CF decreased with child’s worsening disease severity (i.e.,
forced expiratory volume in1sec—FEV1%p r e d i c t e d )a n d
increased as depressive symptoms decreased.
13
Existing studies of caregiver depressive symptoms and
QOL have been conducted in well-controlled research
settings; however, these important caregiver charac-
teristics have not been assessed in clinical settings, such
as CF Clinics. In addition, the extent to which depressive
and anxious symptoms impact QOL in caregivers of
children with CF across childhood and adolescence is not
known. Therefore, the primary aim of this study was to
assess depressive and anxious symptoms in caregivers of
childrenwithCFthroughthefullchilddevelopmentalage
range (ages 0–18), as well as the impact on caregiver
QOL.Becauseofthesparseresearch,wesoughttoinclude
all male caregivers who attended the CF Clinic appoint-
ment.WehypothesizedthatcaregiversofchildrenwithCF
would report elevated depressive and anxious symptoms.
In addition, it was hypothesized that depressive and
anxioussymptomswouldbeinverselyrelatedtocaregiver
QOL. A secondary aim was to examine the relations
between depressive and anxious symptoms and child
health outcomes.
MATERIALS AND METHODS
One hundred eighteen caregivers of children receiving
outpatient care at the CF Clinic were approached for
participation as part of a larger international study aimed
at assessing depressive and anxious symptoms in child
and adult patients with CF and their caregivers (www.
Tides-CF.org).Eightfamiliesdeclined(e.g.,notinterested
in research, not enough time) resulting in a 93% recruit-
ment rate. A total of 100 female and 22 male caregivers
participated. Notably, all male caregivers who were
present for the appointment consented to the study
(i.e., 100% recruitment rate for male caregivers). For
13 families, both female and male caregivers from the
same family attended the CF Clinic visit. With the
exception of patient demographic and medical data, only
caregiverdataarepresentedhere.Thisstudywasapproved
by the Cincinnati Children’s Hospital Medical Center’s
Institutional Review Board.
The CF Team social worker obtained caregiver/adult
patient informed consent and child/adolescent assent.
Next, questionnaires were completed by the caregiver at
a time that was convenient based on the CF Clinic agenda
(i.e.,questionnaireswerecompletedatanytimeduringthe
visit which potentially occurred before or after receiving
FEV1% predicted results). When both female and male
caregivers from the same family were present, they were
instructed to complete the caregiver quality of life-
cystic ﬁbrosis (CQOLCF) independently. Questionnaires
took  15min to complete. Questionnaires were scored
immediately after completion, and for caregivers
who reported clinically elevated depressive or anxious
symptoms in the moderate to severe range, the CF Team
social worker offered outpatient referrals for treatment.
Caregivers completed a basic demographic questionnaire
and measures of depressive and anxious symptoms and
QOL. Health status indicators (e.g., FEV1% predicted
and body mass index (BMI)) were extracted from the
child’s medical record at the time of participation.
Standardized zBMI was also calculated using age- (to
the nearest month) and sex-speciﬁc median, standard
deviation, and power of the Box–Cox transformation
(LMS method) based on national norms from the Centers
for Disease Control.
14
The Hospital Anxiety and Depression Scale (HADS
15)
is comprised of 14 items measuring the cognitive, but not
somaticsymptomsofdepressionandanxiety.Participants
were categorized as having clinically elevated symptoms
based on established clinical cut-off scores of 7 or
ABBREVIATIONS
CES-D center for epidemiological studies-depression 20-item
measure
CF cystic ﬁbrosis
CQOLCF caregiver quality of life-cystic ﬁbrosis 35-item measure
FEV1 forced expiratory volume in 1sec
HADS hospital anxiety and depression scale 14-item measure
QOL quality of life
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15 The HADS has good reliability and validity and
excellent sensitivity and speciﬁcity in patients with
medical conditions and non-illness populations (e.g.,
caregivers, controls).
16,17 In this study, coefﬁcient alphas
were as follows: 0.85 and 0.85 for female caregiver
depressive and anxious symptoms, respectively, and
0.88 and 0.88 for male caregiver depressive and anxious
symptoms, respectively. The HADS was selected for
the larger study because of its short length and focus on
non-somaticsymptoms,whichcanleadtoinﬂatedclinical
elevations in patients with chronic illness, including CF.
However,aspertheprotocolofthelargerstudy,theHADS
was also completed, which has been used with care-
givers.
16,18
To address concerns that the HADS might lead to an
underestimation of depressive symptoms in caregivers,
who do not experience somatic symptoms of CF,
caregivers also completed the Center for Epidemiological
Studies-Depression Scale (CES-D
19). The CES-D is
comprised of 20 items that assesses both somatic and
cognitive symptoms of depression. Again, participants
were categorized as having clinically elevated symptoms
based on established clinical cutoff scores ( 16).
19,20
Higher scores reﬂect endorsement of more depressive
symptoms. In this study, coefﬁcient alpha for the CES-D
was 0.94 for female caregivers and 0.85 for male
caregivers.
The CQOLCF
13 is comprised of 35 items assessing
aspects of CF-speciﬁc QOL including physical (‘‘My
sleep is less restful’’), emotional (‘‘The need to manage
my loved one’s symptoms/illness is overwhelming’’),
family (‘‘Family communication has increased’’), and
social functioning (‘‘I get support from my friends and
neighbors’’). It also includes items about ﬁnancial issues
and spirituality. Respondents were instructed to rate how
true (0¼not at all to 4¼very much) each item is in the
context of caring for someone with CF. Only a total score
is derived from the CQOLCF, ranging from 0 to 140 with
higher scores indicating better QOL.
13 The coefﬁcient
alphafortheCQOLCFwas0.94forfemalecaregiversand
0.84 for male caregivers.
Statistical Analyses
Descriptive data (e.g., means, standard deviations,
proportions) for the HADS, CES-D, and CQOLCF were
presented separately for all female and male caregivers
who participated. Pearson’s correlations were used to
examine relations between caregiver depressive and
anxious symptoms, caregiver QOL, and child health
outcomes.Femaleandmalecaregiverdatawerecombined
for all regression analyses. For the 13 female and male
caregiver dyads, we randomly selected seven female and
six male caregivers for inclusion in the ﬁnal regression
analyses. Two separate hierarchical regression analyses
were conducted to identify predictors of caregiver QOL.
Variables were entered in the following order: child
demographics (i.e., age, FEV1% predicted, zBMI), parent
demographics (i.e., sex, treatment for depression and/or
anxiety), and psychological symptoms (i.e., depressive or
anxious symptoms). In the ﬁrst regression, the indepen-
dent variable of interest was depressive symptoms,
whereas anxious symptoms served as the independent
variable of interest in the second regression equation.
Since the main analysis of interest was the relation
between depressive and anxious symptoms and QOL,
demographic variables were entered earlier in the
regression equation to control for the variance accounted
by them.
21 All analyses were conducted using SPSS
16.0.
22
RESULTS
Participants
Mean age of female caregivers was 37.60 years 
7.78 and male caregivers was 40.58 5.95. Of the female
caregiversreceivingpsychologicaltreatment(i.e.,therapy
only, prescription medication only, or combined therapy
andmedication),6%reportedreceivingcombinedtherapy
andprescriptionmedication.Thirty-onepercentoffemale
caregivers reported being prescribed medication for
depression and/or anxiety and 10.9% reported that they
were receiving therapy. None of the male caregivers
reported receiving psychological treatment. Interestingly,
of those caregivers receiving treatment (n¼30),  50%
reported current clinical elevations of depressive and
anxious symptoms. Descriptive data for patients with CF
and their caregivers are provided in Table 1.
Caregiver Depressive and Anxious Symptoms,
QOL, and Child Health Outcomes
Depressive Symptoms
Twenty-eight percent of female caregivers reported
clinically elevated levels of depressive symptoms on the
CES-D, whereas 20% reported clinical elevations on
the HADS. Child FEV1% predicted was signiﬁcantly
negatively correlated with female caregiver depressive
symptoms as measured by the HADS (P<0.05), whereas
zBMI was not. Correlations between all study variables
are found in Table 2. Approximately 31% of male
caregivers reported clinically elevated depressive symp-
toms on the CES-D, whereas 14% reported elevations as
measured by the HADS. Correlations between male
caregiver depressive symptoms and child FEV1% pre-
dicted and child zBMI were not signiﬁcant. For the
13 caregiver dyads (i.e., female and male caregiver from
same family) 13% of couples reported clinically elevated
depressive symptoms. In addition, as female caregiver
CES-Dsymptomsincreased,sodidmalecaregiverCES-D
symptoms (r¼0.57; P<0.05).
Pediatric Pulmonology
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TABLE 1—Demographics of Patients With CF and their caregivers
N (%) or M (SD); range
Patients
Age 9.42 4.87; 0–17
Sex 57 (51.8%) male
Race
Caucasian 108 (98.2%)
Non-caucasian 2 (1.8%)
Health complications
CFRD 5 (4.5%)
Hemoptysis/pneumothorax 0 (0.0%)
Currently on IVantibiotics 2 (1.8%)
Listed for lung/liver transplant 0 (0.0%)
Health outcomes
Height (cm) 142.91 19.26; 100–183
Weight (kg) 39.29 14.56; 17–75.80
BMI 18.47 2.89; 13.51–27.51
zBMI 0.14 0.91;  2.50 to 1.85
FEV1% predicted 94.22 17.79; 38–128
Disease severity
Normal (FEV1% predicted  90) 57 (51.8%)
Mild (FEV1% predicted 70–89) 24 (21.8%)
Moderate (FEV1% predicted 40–69) 4 (3.6%)
Severe (FEV1% predicted  39) 1 (0.9%)
Caregivers
Age 37.60 7.78; 21–57 (female)
40.58 5.95; 31–50 (male)
Sex 100 females; 22 males
Race
Caucasian 120 (98.4%)
Non-caucasian 2 (1.6%)
Psychological treatment
Therapy 10 (10.9%)
Medication 30 (31.2%)
Therapy and medication 6 (6.0%)
Number of caregivers with more than 1 child diagnosed with CF 6 (5.5%)
HADS scores
Anxiety 7.52 4.16
Depression 4.36 4.07
CES-D 11.23 11.49
TABLE 2—Zero Order Correlations
Patients Female caregivers Male caregivers
Age FEV1% zBMI HADS Dep HADS Anx CESD QOL HADS Dep HADS Anx CESD QOL
Patient
Age —
FEV1%  0.23* —
zBMI  0.21* 0.25* —
Female
HADS Dep  0.15  0.24*  0.03 —
HADS Anx  0.05  0.11  0.09 0.73*** —
CESD  0.01  0.17  0.08 0.79*** 0.79*** —
QOL  0.11 0.28* 0.13  0.72***  0.72***  0.82*** —
Male
HADS Dep  0.28  0.05  0.40 0.34 0.41 0.38  0.26 —
HADS Anx  0.21  0.05  0.35 0.59* 0.80*** 0.72**  0.61* 0.84*** —
CESD  0.34  0.01 0.41 0.43 0.61* 0.57*  0.48 0.74*** 0.88*** —
QOL 0.15 0.06  0.04  0.11  0.60*  0.49 0.26  0.63**  0.70**  0.67*** —
The correlations between female and male caregivers are based on the 13 female–male caregiver dyads in the sample. *P<0.05, **P<0.01,
***P<0.001.
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Fifty-one percent of female caregivers reported
clinically signiﬁcant elevated anxious symptoms. Neither
child FEV1% predicted nor child zBMI was signiﬁcantly
correlated with anxious symptoms for female caregivers.
As female caregiver anxious symptoms increased so did
their depressive symptoms (r¼0.79; P<0.001; see
Table 2). Forty-three percent of male caregivers reported
clinically signiﬁcant elevated anxious symptoms. Neither
child FEV1% predicted nor child zBMI was signiﬁcantly
correlated with anxious symptoms for male caregivers.
For the 13 caregiver dyads, 46% of couples reported
clinically elevated anxious symptoms. As female care-
giver anxious symptoms increased, so did male caregiver
anxious symptoms (r¼0.80; P<0.001). In addition, as
male caregiver anxious symptoms increased so did
their depressive symptoms (r¼0.88; P<0.001; see
Table 2).
Comorbid Symptoms
Twenty-seven percent of female caregivers reported
clinically elevated anxious and depressive symptoms. For
malecaregivers, 33%reportedclinicallyelevated anxious
and depressive symptoms.
QOL
Mean scores on the CQOLCF were 97.74 23.36 for
female caregivers. For female caregivers, lower QOL
was related to better child lung functioning (r¼0.28;
P<0.05; see Table 2) and fewer depressive (r¼ 0.82;
P<0.001) and anxious (r¼ 0.72; P<0.001) symp-
toms. Mean scores on the CQOLCF were 100.65 
15.83 for male caregivers. Better QOL for male
caregivers was also related to fewer depressive
(r¼ 0.67; P<0.001) and anxious symptoms (r¼
  0.70; P<0.001; see Table 2).
Predictors of QOL
To determine whether CES-D or HADS Depression
scoreswereabetterpredictorofcaregiverQOL,bothwere
entered into the same regression equation. CES-D
scores (b¼ 0.692, P<0.001), but not HADS Depres-
sion scores (b¼ 0.156, P¼0.091), signiﬁcantly pre-
dicted QOL. Therefore, all hierarchical regression
analysesusedCES-Dscoresastheindicatorofdepressive
symptoms.
Two hierarchical regression analyses were conducted
to identify signiﬁcant predictors of caregiver QOL
(see Table 3). For both regressions, caregiver QOL
was the dependent variable, child age, child FEV1%
predicted, and zBMI were entered into Step 1, and
caregiver sex and whether caregivers received psycho-
logical treatment (medication and/or therapy) were
entered into Step 2.
In the ﬁrst hierarchical regression, HADS Anxiety
scores were entered into Step 3 to control for thevariance
attributed to anxious symptoms and CES-D scores were
enteredintoStep4.AlthoughFEV1%predicted(b¼0.15,
P¼0.058) marginally predicted, and anxious symptoms
(b¼ 0.63, P<0.001) uniquely predicted caregiver
QOL in Step 3, the addition of CES-D scores in Step 4
of the regression resulted in a signiﬁcant increase
in R
2 (DR
2¼0.137, Finc(1, 71)¼36.94, P<0.001), with
depressive symptoms (b¼ 0.63, P<0.001) signiﬁ-
cantly predicting QOL (see Table 3).
In the second hierarchical regression, the same
demographic variables as described previously were
entered into Steps 1 and 2. Caregiver CES-D scores
were entered into Step 3 to control for the variance
attributed to depressive symptoms and HADS Anxiety
scores were entered into Step 4. The addition of HADS
AnxietyscoresinStep4oftheregressiondidnotresultina
signiﬁcantincreaseinR
2(DR
2¼0.008,Finc(1,71)¼2.17,
P¼0.145) above that which was predicted by CES-D
scores (b¼ 0.63, P<0.001; Table 3).
1
DISCUSSION
This study found elevated levels of depressive symp-
toms based on established clinical cutoffs of the HADS
and CES-D
15,19,20 in caregivers of children with CF who
ranged in age from birth to 18. Our ﬁndings extend
previous studies regarding depression in caregivers of
young children with CF.
7,8 Furthermore, this is the
ﬁrst study to demonstrate high rates (nearly 50%) of
anxious symptoms in caregivers of children with CF.
15,16
Femalecaregiversreportedhigherratesofbothdepressive
and anxious symptoms than male caregivers. Notably,
30% of female caregivers reported being prescribed
medication for depression and/or anxiety. Despite receiv-
ing treatment in the form of medication and/or therapy,
50% of female caregivers continued to experience
clinically elevated symptoms. In addition, presence of
comorbid depressive and anxious symptoms in both
female and male caregivers was high. These elevated
rates highlight the importance of attending to the
psychological functioning of caregivers of children
with CF especially because psychological symptoms
impact daily tasks,
23 as well as adherence to treatment
regimens.
22–24 Moreover, the highly demanding, costly,
and time-consuming treatment regimen associated
Pediatric Pulmonology
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overlap in items and whether there is confounding of the predictors as a
result. Three items from the CES-D were identiﬁed as overlapping with three
items on the CQOLF. Therefore, to provide a stricter test of the regression
models, thosethree items were deletedfrom the CQOLCF and the total score
was recalculated. The regression analyses described in the previous
paragraphs were repeated with the recalculated CQOLCF total score as the
dependent variable. Importantly, the pattern of results remained unchanged.
788 Driscoll et al.with caring for a child with CF (e.g., frequent clinic
appointments and hospitalizations, lengthy daily treat-
ments) coupled with concern about the child’s shortened
life expectancy may be factors that contribute to the
onset of depressive symptoms in caregivers. Given that
the broader pediatric literature has demonstrated a
link between parent and child psychological adapta-
tion,
25,26 it is also important to examine the role of
caregiver depressive and anxious symptoms on similar
symptoms in children with CF.
Our results revealed higher rates (i.e., 31%) of
depressive symptoms on the CES-D among male care-
givers than on the HADS (i.e., 14%), whereas, the two
measures revealed comparable rates among female care-
givers(i.e.,28%forCES-D,20%forHADS).Itisunclear
why rates of depressive symptoms in male caregivers
differed based on the measure used. Nevertheless, addi-
tional research is needed to determine the utility of the
HADS given that a measure of anxiety assessing somatic
symptoms was not included in the present study. The
Pediatric Pulmonology
TABLE 3—Concurrent Associations Between Depressive and Anxious Symptoms and
QOL
Variable B SE B b R
2 DR
2 f
2
Step 1 0.16***
Age 1.32 0.71 0.20
FEV1% predicted 0.50 0.15 0.38***
zBMI 1.13 2.79 0.05
Step 2 0.33*** 0.17*** 0.25
Age 0.82 0.66 0.13
FEV1% predicted 0.36 0.14 0.27*
zBMI 1.35 2.53 0.05
Caregiver sex  1.86 6.06  0.03
Caregiver treatment  21.04 5.09  0.43***
Predictor¼depressive symptoms
Step 3 0.60*** 0.27*** 0.68
Age  0.15 0.53  0.02
FEV1% predicted 0.20 0.11 0.15
þ
zBMI 2.58 1.97 0.10
Caregiver sex  1.34 4.70  0.02
Caregiver treatment  8.00 4.37  0.17
þ
HADS Anxiety  3.41 0.49  0.63***
Step 4 0.74*** 0.14*** 0.54
Age 0.04 0.43 0.01
FEV1% predicted 0.15 0.09 0.11
zBMI 2.79 1.61 0.11
Caregiver sex  1.05 3.84  0.02
Caregiver treatment  4.68 3.61  0.10
HADS Anxiety  0.85 0.58  0.16
CES-D  1.17 0.19  0.63***
Predictor¼anxious symptoms
Step 3 0.73*** 0.40***  0.60
Age 0.18 0.43 0.03
FEV1% predicted 0.16 0.09 0.12
þ
zBMI 2.68 1.62 0.11
Caregiver sex  1.06 3.87  0.02
Caregiver treatment  5.64 3.58  0.12
CES-D  1.38 0.13  0.75***
Step 4 0.74 0.01 0.04
Age 0.04 0.43 0.01
FEV1% predicted 0.15 0.09 0.11
zBMI 2.79 1.61 0.11
Caregiver sex  1.05 3.84  0.02
Caregiver treatment  4.68 3.61  0.10
CES-D  1.17 0.19  0.63***
HADS Anxiety  0.85 0.58  0.16
B,unstandardizedbetaweight;SEB,standarderroroftheunstandardizedbetaweight;b,standardized beta
weight;R
2,squaredmultiplecorrelation;DR
2,changeinthesquaredmultiplecorrelation;f
2,Cohen’seffect
size; Caregiver treatment, prescription medication and/or therapy.
*P<0.05, **P<0.01, ***P<0.001,
þP approaching signiﬁcance.
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contributed to efﬁciency of data collection during routine
CF Clinic appointments; however, current results support
theuseofmeasuresthatincludesomaticitems(e.g.,CES-
D,StateTraitAnxietyInventory,BeckAnxietyInventory)
to avoid underestimation of symptoms.
The sample size of male caregivers was modest, which
resultedfromthefactthatfemalecaregiversaccompanied
their children to CF Clinic appointments more than male
caregivers. However, this is one of few studies in CF
to assess male caregivers’ psychological functioning.
Speciﬁcally, results indicated that male caregivers
reported a greater number of anxious than depressive
symptoms. Although we were unable to determine
whether the male caregivers who attended CF Clinic
differed signiﬁcantly from thosewho did not, the fact that
they reported elevations of psychological symptoms
highlights the importance of attending to the needs of
those who did attend and efforts should be made to
increase male caregivers’ participation in future studies.
Another important ﬁnding of the current study was the
high symptom rates among female and male caregivers
from the same couple; 13% and 46% of couples reported
elevated depressive and anxious symptoms, respectively.
Again, the sample size of couples was modest, but these
rates raise an important issue for future studies. It will be
important to determine if higher rates are a result of
illness-related factors, such as fewer economic resources,
lower family support regarding treatment-related burden,
and marital dissatisfaction. Alternatively, symptom con-
tagion
27,28amongcouplesinwhichonememberdevelops
symptoms as a result of the other’s symptoms, and
assortative pairing in which there is differential associa-
tion with symptomatic partners
29 may play a role too.
Factors associated with higher rates of psychological
distress in couples are particularly relevant since parents
appear morevulnerable topsychological difﬁculties (e.g.,
depression) especially when a diagnosis of CF is made
within the ﬁrst few months of life.
8
With regard to the relations between caregiver symp-
toms and health status, better child lung functioning was
associated with fewer depressive symptoms and better
QOL in female caregivers. These ﬁndings suggest that
lung functioning may play a greater role in determining
caregiver mood as most of the morbidity and mortality in
CF is due to respiratory infection and disease. Since
female caregivers tend to bear more responsibility for the
primary care of children, they could have more difﬁculty
adaptingtochangesindiseasestatus.Alternatively,itmay
be that male caregivers are not as attuned to negative
healthchangesonadailybasisbecauseoftheirpotentially
more distal role in caregiving. Another explanation is that
female caregivers who experience depressive symptoms
may not be able to adequately help their children manage
CF, leading to poor adherence,
23,30,31 and ultimately,
worse lung functioning. Future studies involving male
caregivers will help to determine the impact of their
children’s health outcomes (e.g., lung functioning and
weight)ontheirownsymptomsofanxietyanddepression.
Additionally, we did not control for the timing of
questionnairecompletioninthisstudy.Thus,itisplausible
that anticipation of FEV1% predicted results led to higher
symptom endorsement. Alternatively, FEV1% predicted
results learned prior to completion of the questionnaires
couldhaveincreasedordecreasedsymptomendorsement.
Therefore, it will be important to investigate the role
of FEV1% predicted results on immediate reporting of
symptomsinfuturestudies.Forthosecaregiverswhohave
a history of depressive or anxious symptoms, effective
interventions need to be developed that are time-limited
and do not add burden to an already difﬁcult and time-
consuming disease management regimen.
Overall,caregiversreportedexperiencingpositivedaily
functioning and psychological well-being (e.g., QOL
32).
Although the caregiver QOL measure used in this study
provided only a general indicator of QOL (as opposed to
subscales), it is the only CF-speciﬁc measure of caregiver
QOL in the current literature, a relative strength of the
current study. Speciﬁc areas potentially impacted by CF,
such as social functioning and treatment burden are
worthy of future exploration if new measures are
developed. Caregiver QOL was associated with both
depressive and anxious symptoms, with lower symptoms
associated with better QOL, which is likely due to QOL
being a broad construct that captures psychological
functioning. Although depressive and anxious symptoms
uniquely predicted caregiver QOL, even after controlling
for whether caregivers were receiving psychological
treatment, there was a stronger relation between depres-
sivesymptomsandQOL.Thecross-sectionalnatureofthe
data limits our conclusions about causality and the long-
termimpactofdepressiveandanxioussymptomsonQOL,
as does the lack of an age matched healthy control group.
Longitudinal studies that statistically control for initial
depressive and anxious symptoms would potentially
clarify these issues while accounting for some shared
methodvariance.Inaddition,prioritizingimplementation
of interventions for depressive symptoms may lead to
improvement in caregiver QOL, as alleviation of anxious
symptoms is likely since common treatments are used
for both disorders (e.g., cognitive-behavioral therapy,
medication).
In conclusion, the results of this study demonstrated
a clear need to address the psychological health and well-
being of caregivers of children with CF. Assessment of
psychological symptoms can be easily incorporated into
a routine CF Clinic appointment. The US Preventive
Services Task Force recommends routine depression
screening among adults.
33 Although the best measure to
use has not been determined, it appears that using
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790 Driscoll et al.measures such as the CES-D are warranted as part of the
routine CF Clinic appointment. Our study suggests
that screening measures for anxiety may also be
beneﬁcial. CF Teams are in the best position to assist
with problem-solving around CF-speciﬁc stressors that
may contribute to caregiver depressive and anxious
symptoms. In addition, assessment of depressive and
anxious symptoms presents opportunities for discus-
sion about caregiver psychological health and pro-
vision of referrals for comprehensive assessment and
intervention.
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